NAT2 and tuberculosis: Prior to the present work, multiple studies have highlighted the importance of different NAT2 polymorphisms, especially the slow acetylator phenotype, in susceptibility to drug-induced hepatotoxicity, particularly in the context of anti-tuberculosis treatment.